So far, such treatment options for JAK3 deficiencies leading to SCID have not been described; however, due to the pathomolecular and clinical similarities between X-SCID and JAK3-SCID, it seems promising to genetically correct autologous stem cells of affected individuals using new molecular tools such as CRISPR/Cas9 and thus establish a new curative treatment option. The gene discussed is JAK3; the disease is T-B+ severe combined immunodeficiency due to gamma chain deficiency.